Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600640 | 0.84 | GRM5 (0.36) | CYP11B1CYP11B2CD274 | |
| SCHEMBL31175615 | 0.83 | OPRM1 (0.37) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL16600198 | 0.82 | CYP11B1 (0.41) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL31622174 | 0.81 | SMN1; SMN2 (0.34) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL26112063 | 0.76 | LMNA (0.35) | — | |
| SCHEMBL31580332 | 0.74 | CYP11B1 (0.40) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL25809394 | 0.74 | TET3 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL17925559 | 0.74 | DDB1 (0.42) | SMN1; SMN2CYP11B2 | |
| SCHEMBL29626701 | 0.73 | CYP11B1 (0.39) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 | |
| SCHEMBL23260104 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP11B1CYP11B2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | SMN1; SMN2 2892/4885CYP11B1 4578/4885CYP11B2 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.